11
5 “Forever” Dividend Stocks Paying Retirees Rich Yields
5 High-Yield Dividend Stocks Retirees Can Buy and Hold Forever
Quick Summary: Looking for steady income in retirement? We break down five companies paying strong dividends — from tobacco to telecom to pharmaceuticals. Each has a different story, but all aim to put cash in your pocket regularly.
Why Dividend Stocks Matter for Retirees
Imagine you own a small piece of a business. When that business makes money, it can send you a "thank you" check every few months. That’s a dividend. For retirees, these checks can help pay bills without selling your investments.
But not all high yields are safe. Some are "yield traps" — the payout looks big, but the company might cut it soon. The five stocks below were chosen for cash-flow durability (ability to keep paying) as of July 14, 2026.
Important Tax Note: Philip Morris International is based in Switzerland. U.S. investors usually face a 15% Swiss withholding tax on dividends. You can often claim this back via the foreign tax credit in taxable accounts, but not in IRAs.
1. Altria (NYSE: MO) — The Cash Cow
Yield: 5.67% | Recent Price: $74.82 | Quarterly Dividend: $1.06
Why It’s Interesting
- Cheap valuation: Forward P/E of just 13 (you pay $13 for $1 of expected earnings)
- Strong profits: Smokeable products (cigarettes) still deliver 65% profit margins
- Guidance intact: FY2026 adjusted EPS forecast of $5.56–$5.72
- Stock up 27% over the past year
The Risk
- Volumes declining: U.S. cigarette volumes down ~5%
- Market share slipping: Marlboro lost 1.4 points (now 39.7%);
on!nicotine pouches lost 4.2 points (now 13.4%) - Long-term challenge: Fewer smokers each year — pricing power must keep outrunning volume loss
2. Philip Morris International (NYSE: PM) — The Growth + Income Hybrid
Yield: 2.94% | Quarterly Dividend: $1.47 (up from $1.35 in H1 2025)
Why It’s Interesting
- Fastest dividend growth on this list
- Smoke-free future: IQOS (heated tobacco) in 108 markets, ZYN (nicotine pouches) in 58 markets
- Smoke-free = 41.5% of revenue and growing
- EPS guidance: $8.36–$8.51 for FY2026 (11–13% jump)
- Long-term target: 9–11% annual EPS growth through 2028 (ex-currency)
- Analyst price target: $194.86
The Risk
- ZYN shipments fell 23.5% in Q1 (distributor destocking)
- Buybacks paused to pay down debt
- Swiss withholding tax applies (see callout above)
3. AT&T (NYSE: T) — The Turnaround Story
New Quarterly Dividend: $0.33 (up 20% from $0.27 held for 16 quarters!)
Annualized Yield: ~$1.3376/share | Ex-Dividend Date: July 17 | Payable: Aug 3
Why It’s Interesting
- First raise in 4 years — signal of confidence
- Massive cash flow target: $18B+ free cash flow in FY2026
- Shareholder return plan: $45 billion total (dividends + buybacks) through 2028
- Conservative payout: Dividend covered by roughly half of 2025 EPS ($2.11)
- Q1 EPS up 11.8% year-over-year
The Risk
- Heavy debt: $138.4 billion total
- Leverage rising: Net debt/EBITDA expected toward 3.2x after EchoStar deal
- Stock still down 16.35% over past year
4. Pfizer (NYSE: PFE) — The Ultra-High Yield
Yield: 6.81% | Recent Price: ~$25.25 | Quarterly Dividend: $0.43
Why It’s Interesting
- Highest yield in the group
- Earnings recovery underway: Q1 2026 adjusted EPS $0.75 on $14.45B revenue (+5.4% YoY)
- Dividend well-covered: FY2026 EPS guidance $2.80–$3.00 vs. $1.72 annualized dividend
- Key drug protected: Vyndamax U.S. exclusivity extended to June 2031
- Very cheap: Forward P/E of 8 (market expects bad news)
The Risk
- COVID products collapsing: Comirnaty -59%, Paxlovid -63%
- $1.5B revenue headwind in 2026 from loss of exclusivity
- Policy risk: Most-Favored-Nation drug pricing proposals
5. T. Rowe Price (NASDAQ: TROW) — The Dividend Aristocrat
Yield: 4.27% | Quarterly Dividend: $1.30 | Price: $121.68
Why It’s Interesting
- Elite track record: Dividend increased every year since at least 1999 — never cut
- Debt-free balance sheet with $3.73B in cash
- Strong Q1: Adjusted EPS $2.52 (beat $2.35 estimate), revenue $1.86B
- Assets growing: Average AUM $1.78 trillion (+9.6% YoY)
- Shareholder friendly: Returned $629M in Q1 alone
The Risk
- Clients pulling money: $13.7B net outflows in Q1, $56.9B in FY2025
- Fees compressing: Down to 38.4 basis points
- Analysts skeptical: 9 Holds, 1 Sell, 3 Strong Sells | Price target $106.33 (below current $121.68)
- You’re paying for safety, not growth
Side-by-Side Comparison
| Company | Ticker | Yield | Quarterly Div | Key Strength | Main Risk |
|---|---|---|---|---|---|
| Altria | MO | 5.67% | $1.06 | Huge margins, cheap valuation | Declining cigarette volumes |
| Philip Morris | PM | 2.94% | $1.47 | Fastest dividend growth, smoke-free pivot | ZYN slowdown, Swiss tax |
| AT&T | T | ~5.3%* | $0.33 | Major dividend raise, $45B return plan | High debt, leveraged |
| Pfizer | PFE | 6.81% | $0.43 | Highest yield, earnings recovering | COVID cliff, patent cliffs |
| T. Rowe Price | TROW | 4.27% | $1.30 | 25+ years of raises, zero debt | Outflows, fee pressure, rich valuation |
*AT&T yield estimated from new $1.3376 annualized rate at recent price.
How to Think About These as a Retiree
Step 1: Know Your Income Need
How much cash do you need from investments each year? Divide by the yield to see how much to invest.
Step 2: Check the "Safety Margin"
- Payout ratio: Is earnings >> dividend? (Pfizer: yes. AT&T: yes. Altria: yes.)
- Debt: Can they survive a downturn? (TROW: zero debt. PM: paying it down. AT&T: high but managing.)
- History: Have they cut before? (TROW: never. Others: mixed.)
Step 3: Diversify Across Sectors
These five cover:
- Tobacco/Nicotine (MO, PM)
- Telecom (T)
- Pharma (PFE)
- Asset Management (TROW)
Step 4: Watch the Tax Bucket
- Taxable account: Foreign tax credit helps with PM
- IRA/401(k): PM’s 15% Swiss tax is lost forever — consider MO instead for tobacco exposure
Step 5: Revisit Annually
- Did earnings cover the dividend?
- Is the thesis still intact?
- Has the yield become a trap?
Summary
| If You Want… | Consider… |
|---|---|
| Highest current income | Pfizer (6.81%) — but watch patent cliffs |
| Best dividend growth | Philip Morris — smoke-free transition driving raises |
| Proven never-cut history | T. Rowe Price — 25+ years, zero debt |
| Turnaround + big raise | AT&T — first hike in 4 years, $45B return plan |
| Cheap valuation + big margins | Altria — but volumes keep shrinking |
No stock is risk-free. The goal is durable cash flow — companies where profits reliably exceed dividends, even in tough times.
FAQ
1. What does "forward P/E" mean?
It’s the stock price divided by next year’s estimated earnings per share. Lower = cheaper. Altria at 13 means you pay $13 for each $1 of expected profit. Pfizer at 8 is even cheaper — but the market worries about future profits.
2. Why does Philip Morris have a Swiss tax?
PMI is legally domiciled in Switzerland. The Swiss government takes 15% of dividends before you get them. In a regular brokerage account, you file Form 1116 to get it back. In an IRA, you cannot recover it — it’s gone.
3. What’s a "Dividend Aristocrat"?
A company in the S&P 500 that has raised its dividend for at least 25 consecutive years. T. Rowe Price qualifies. It signals management prioritizes shareholders.
4. Is a 6.8% yield (Pfizer) too good to be true?
High yields often signal market fear. Investors worry Pfizer’s COVID windfall is gone and new drugs won’t replace it. The low P/E (8) says "we don’t believe earnings will hold." If earnings do hold, the stock could rerate higher. If not, the dividend could be cut.
5. Should I buy all five?
Only if it fits your total portfolio. Five stocks isn’t enough diversification. Consider:
- Sector limits (two tobacco names = concentrated risk)
- Account type (PM tax drag in IRAs)
- Your personal risk tolerance
- Talk to a fee-only financial advisor before acting.
Data as of July 14, 2026. This article is for informational purposes only and does not constitute investment advice. Always do your own research or consult a qualified professional.
